WO2023231049A1 - 一种促进创面无瘢痕愈合的抗菌敷料及其制备方法 - Google Patents
一种促进创面无瘢痕愈合的抗菌敷料及其制备方法 Download PDFInfo
- Publication number
- WO2023231049A1 WO2023231049A1 PCT/CN2022/097163 CN2022097163W WO2023231049A1 WO 2023231049 A1 WO2023231049 A1 WO 2023231049A1 CN 2022097163 W CN2022097163 W CN 2022097163W WO 2023231049 A1 WO2023231049 A1 WO 2023231049A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- parts
- scar
- hyperbranched polylysine
- complex
- healing
- Prior art date
Links
- 230000000844 anti-bacterial effect Effects 0.000 title claims abstract description 36
- 206010052428 Wound Diseases 0.000 title claims abstract description 34
- 208000027418 Wounds and injury Diseases 0.000 title claims abstract description 34
- 230000035876 healing Effects 0.000 title claims abstract description 22
- 230000001737 promoting effect Effects 0.000 title claims abstract description 9
- 238000002360 preparation method Methods 0.000 title claims abstract description 6
- 229920000656 polylysine Polymers 0.000 claims abstract description 51
- 108010039918 Polylysine Proteins 0.000 claims abstract description 49
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims abstract description 34
- 239000002562 thickening agent Substances 0.000 claims abstract description 18
- 230000029663 wound healing Effects 0.000 claims abstract description 18
- NIXOWILDQLNWCW-UHFFFAOYSA-N Acrylic acid Chemical compound OC(=O)C=C NIXOWILDQLNWCW-UHFFFAOYSA-N 0.000 claims abstract description 17
- 239000003814 drug Substances 0.000 claims abstract description 16
- 229940079593 drug Drugs 0.000 claims abstract description 15
- 229920002125 Sokalan® Polymers 0.000 claims abstract description 8
- 229960001631 carbomer Drugs 0.000 claims abstract description 8
- 239000000419 plant extract Substances 0.000 claims abstract description 7
- 230000003020 moisturizing effect Effects 0.000 claims abstract description 6
- 239000003513 alkali Substances 0.000 claims abstract description 4
- 239000003795 chemical substances by application Substances 0.000 claims abstract description 4
- KFZMGEQAYNKOFK-UHFFFAOYSA-N Isopropanol Chemical compound CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 claims description 41
- 239000000243 solution Substances 0.000 claims description 39
- PEDCQBHIVMGVHV-UHFFFAOYSA-N glycerol group Chemical group OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 claims description 24
- 238000003756 stirring Methods 0.000 claims description 21
- 238000006243 chemical reaction Methods 0.000 claims description 19
- 231100000241 scar Toxicity 0.000 claims description 17
- 238000003760 magnetic stirring Methods 0.000 claims description 12
- 238000000034 method Methods 0.000 claims description 12
- 239000000203 mixture Substances 0.000 claims description 11
- LMDZBCPBFSXMTL-UHFFFAOYSA-N 1-ethyl-3-(3-dimethylaminopropyl)carbodiimide Chemical compound CCN=C=NCCCN(C)C LMDZBCPBFSXMTL-UHFFFAOYSA-N 0.000 claims description 10
- 239000008367 deionised water Substances 0.000 claims description 10
- 229910021641 deionized water Inorganic materials 0.000 claims description 10
- 239000011259 mixed solution Substances 0.000 claims description 10
- NQTADLQHYWFPDB-UHFFFAOYSA-N N-Hydroxysuccinimide Chemical compound ON1C(=O)CCC1=O NQTADLQHYWFPDB-UHFFFAOYSA-N 0.000 claims description 9
- 241000219357 Cactaceae Species 0.000 claims description 8
- 239000000284 extract Substances 0.000 claims description 8
- 239000007864 aqueous solution Substances 0.000 claims description 6
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 claims description 5
- 239000011550 stock solution Substances 0.000 claims description 5
- NLVXSWCKKBEXTG-UHFFFAOYSA-N vinylsulfonic acid Chemical compound OS(=O)(=O)C=C NLVXSWCKKBEXTG-UHFFFAOYSA-N 0.000 claims description 5
- SNKFFCBZYFGCQN-UHFFFAOYSA-N 2-[3-[3-[1-carboxy-2-(3,4-dihydroxyphenyl)ethoxy]carbonyl-2-(3,4-dihydroxyphenyl)-7-hydroxy-2,3-dihydro-1-benzofuran-4-yl]prop-2-enoyloxy]-3-(3,4-dihydroxyphenyl)propanoic acid Chemical compound C=1C=C(O)C=2OC(C=3C=C(O)C(O)=CC=3)C(C(=O)OC(CC=3C=C(O)C(O)=CC=3)C(O)=O)C=2C=1C=CC(=O)OC(C(=O)O)CC1=CC=C(O)C(O)=C1 SNKFFCBZYFGCQN-UHFFFAOYSA-N 0.000 claims description 4
- SNKFFCBZYFGCQN-VWUOOIFGSA-N Lithospermic acid B Natural products C([C@H](C(=O)O)OC(=O)\C=C\C=1C=2[C@H](C(=O)O[C@H](CC=3C=C(O)C(O)=CC=3)C(O)=O)[C@H](OC=2C(O)=CC=1)C=1C=C(O)C(O)=CC=1)C1=CC=C(O)C(O)=C1 SNKFFCBZYFGCQN-VWUOOIFGSA-N 0.000 claims description 4
- 108090000526 Papain Proteins 0.000 claims description 4
- 239000004365 Protease Substances 0.000 claims description 4
- QCYLIQBVLZBPNK-UHFFFAOYSA-N asiaticoside A Natural products O1C(C(=O)C(C)C)=CC(C)C(C2(C(OC(C)=O)CC34C5)C)C1CC2(C)C3CCC(C1(C)C)C45CCC1OC1OCC(O)C(O)C1O QCYLIQBVLZBPNK-UHFFFAOYSA-N 0.000 claims description 4
- 229940055729 papain Drugs 0.000 claims description 4
- 235000019834 papain Nutrition 0.000 claims description 4
- STCJJTBMWHMRCD-UHFFFAOYSA-N salvianolic acid B Natural products OC(=O)C(Cc1ccc(O)c(O)c1)OC(=O)C=Cc2cc(O)c(O)c3OC(C(C(=O)OC(Cc4ccc(O)c(O)c4)C(=O)O)c23)c5ccc(O)c(O)c5 STCJJTBMWHMRCD-UHFFFAOYSA-N 0.000 claims description 4
- WYQVAPGDARQUBT-FGWHUCSPSA-N Madecassol Chemical compound O([C@@H]1[C@@H](CO)O[C@H]([C@@H]([C@H]1O)O)OC[C@H]1O[C@H]([C@@H]([C@@H](O)[C@@H]1O)O)OC(=O)[C@]12CC[C@H]([C@@H]([C@H]1C=1[C@@]([C@@]3(CC[C@H]4[C@](C)(CO)[C@@H](O)[C@H](O)C[C@]4(C)[C@H]3CC=1)C)(C)CC2)C)C)[C@@H]1O[C@@H](C)[C@H](O)[C@@H](O)[C@H]1O WYQVAPGDARQUBT-FGWHUCSPSA-N 0.000 claims description 3
- 239000004909 Moisturizer Substances 0.000 claims description 3
- 229940069521 aloe extract Drugs 0.000 claims description 3
- WYQVAPGDARQUBT-XCWYDTOWSA-N asiaticoside Natural products O=C(O[C@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO[C@H]2[C@H](O)[C@H](O)[C@H](O[C@H]3[C@H](O)[C@H](O)[C@@H](O)[C@H](C)O3)[C@@H](CO)O2)O1)[C@@]12[C@@H]([C@@H](C)[C@H](C)CC1)C=1[C@](C)([C@@]3(C)[C@@H]([C@@]4(C)[C@H]([C@@](CO)(C)[C@@H](O)[C@H](O)C4)CC3)CC=1)CC2 WYQVAPGDARQUBT-XCWYDTOWSA-N 0.000 claims description 3
- 229940022757 asiaticoside Drugs 0.000 claims description 3
- 230000001333 moisturizer Effects 0.000 claims description 3
- 239000004354 Hydroxyethyl cellulose Substances 0.000 claims description 2
- 229920000663 Hydroxyethyl cellulose Polymers 0.000 claims description 2
- 239000004372 Polyvinyl alcohol Substances 0.000 claims description 2
- 235000019447 hydroxyethyl cellulose Nutrition 0.000 claims description 2
- 239000001866 hydroxypropyl methyl cellulose Substances 0.000 claims description 2
- 229920003088 hydroxypropyl methyl cellulose Polymers 0.000 claims description 2
- 235000010979 hydroxypropyl methyl cellulose Nutrition 0.000 claims description 2
- UFVKGYZPFZQRLF-UHFFFAOYSA-N hydroxypropyl methyl cellulose Chemical compound OC1C(O)C(OC)OC(CO)C1OC1C(O)C(O)C(OC2C(C(O)C(OC3C(C(O)C(O)C(CO)O3)O)C(CO)O2)O)C(CO)O1 UFVKGYZPFZQRLF-UHFFFAOYSA-N 0.000 claims description 2
- 229920002451 polyvinyl alcohol Polymers 0.000 claims description 2
- 235000019422 polyvinyl alcohol Nutrition 0.000 claims description 2
- 229920000036 polyvinylpyrrolidone Polymers 0.000 claims description 2
- 239000001267 polyvinylpyrrolidone Substances 0.000 claims description 2
- 235000013855 polyvinylpyrrolidone Nutrition 0.000 claims description 2
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 claims 3
- RFRMMZAKBNXNHE-UHFFFAOYSA-N 6-[4,6-dihydroxy-5-(2-hydroxyethoxy)-2-(hydroxymethyl)oxan-3-yl]oxy-2-(hydroxymethyl)-5-(2-hydroxypropoxy)oxane-3,4-diol Chemical compound CC(O)COC1C(O)C(O)C(CO)OC1OC1C(O)C(OCCO)C(O)OC1CO RFRMMZAKBNXNHE-UHFFFAOYSA-N 0.000 claims 1
- 238000006845 Michael addition reaction Methods 0.000 claims 1
- GSEJCLTVZPLZKY-UHFFFAOYSA-N Triethanolamine Chemical compound OCCN(CCO)CCO GSEJCLTVZPLZKY-UHFFFAOYSA-N 0.000 claims 1
- 239000012670 alkaline solution Substances 0.000 claims 1
- 239000012064 sodium phosphate buffer Substances 0.000 claims 1
- 125000003396 thiol group Chemical class [H]S* 0.000 claims 1
- 230000036573 scar formation Effects 0.000 abstract description 5
- 239000000126 substance Substances 0.000 abstract description 4
- 230000009286 beneficial effect Effects 0.000 abstract description 3
- 239000003906 humectant Substances 0.000 abstract description 2
- 150000001875 compounds Chemical class 0.000 abstract 2
- 239000000499 gel Substances 0.000 description 24
- 208000032544 Cicatrix Diseases 0.000 description 9
- 235000011187 glycerol Nutrition 0.000 description 9
- 230000037387 scars Effects 0.000 description 9
- 206010061218 Inflammation Diseases 0.000 description 6
- 230000004054 inflammatory process Effects 0.000 description 6
- 239000003002 pH adjusting agent Substances 0.000 description 6
- 235000014104 aloe vera supplement Nutrition 0.000 description 5
- 229940049638 carbomer homopolymer type c Drugs 0.000 description 5
- 229940043234 carbomer-940 Drugs 0.000 description 5
- 238000001816 cooling Methods 0.000 description 5
- 230000000694 effects Effects 0.000 description 5
- 239000012467 final product Substances 0.000 description 4
- 230000002401 inhibitory effect Effects 0.000 description 4
- 206010020718 hyperplasia Diseases 0.000 description 3
- 150000002500 ions Chemical class 0.000 description 3
- 229920001296 polysiloxane Polymers 0.000 description 3
- 108090000623 proteins and genes Proteins 0.000 description 3
- 102000004169 proteins and genes Human genes 0.000 description 3
- 210000003491 skin Anatomy 0.000 description 3
- 238000012360 testing method Methods 0.000 description 3
- 241000222122 Candida albicans Species 0.000 description 2
- 241000588724 Escherichia coli Species 0.000 description 2
- 241000589517 Pseudomonas aeruginosa Species 0.000 description 2
- 241000191967 Staphylococcus aureus Species 0.000 description 2
- 229940095731 candida albicans Drugs 0.000 description 2
- 230000006378 damage Effects 0.000 description 2
- 210000002950 fibroblast Anatomy 0.000 description 2
- 230000006870 function Effects 0.000 description 2
- 230000003340 mental effect Effects 0.000 description 2
- 230000004048 modification Effects 0.000 description 2
- 238000012986 modification Methods 0.000 description 2
- 210000000056 organ Anatomy 0.000 description 2
- 230000001575 pathological effect Effects 0.000 description 2
- 230000008569 process Effects 0.000 description 2
- 239000000047 product Substances 0.000 description 2
- 230000035755 proliferation Effects 0.000 description 2
- 230000037390 scarring Effects 0.000 description 2
- 230000008685 targeting Effects 0.000 description 2
- JVTIXNMXDLQEJE-UHFFFAOYSA-N 2-decanoyloxypropyl decanoate 2-octanoyloxypropyl octanoate Chemical compound C(CCCCCCC)(=O)OCC(C)OC(CCCCCCC)=O.C(=O)(CCCCCCCCC)OCC(C)OC(=O)CCCCCCCCC JVTIXNMXDLQEJE-UHFFFAOYSA-N 0.000 description 1
- WLAMNBDJUVNPJU-UHFFFAOYSA-N 2-methylbutyric acid Chemical compound CCC(C)C(O)=O WLAMNBDJUVNPJU-UHFFFAOYSA-N 0.000 description 1
- 206010001488 Aggression Diseases 0.000 description 1
- 206010003694 Atrophy Diseases 0.000 description 1
- 241000894006 Bacteria Species 0.000 description 1
- 102000008186 Collagen Human genes 0.000 description 1
- 108010035532 Collagen Proteins 0.000 description 1
- 102000010834 Extracellular Matrix Proteins Human genes 0.000 description 1
- 108010037362 Extracellular Matrix Proteins Proteins 0.000 description 1
- 206010016654 Fibrosis Diseases 0.000 description 1
- 208000002260 Keloid Diseases 0.000 description 1
- BNMGUJRJUUDLHW-HCZMHFOYSA-N Madecassoside Chemical compound O([C@@H]1[C@@H](CO)O[C@H]([C@@H]([C@H]1O)O)OC[C@H]1O[C@H]([C@@H]([C@@H](O)[C@@H]1O)O)OC(=O)[C@]12CC[C@H]([C@@H]([C@H]1C=1[C@@]([C@@]3(C[C@@H](O)[C@H]4[C@](C)(CO)[C@@H](O)[C@H](O)C[C@]4(C)[C@H]3CC=1)C)(C)CC2)C)C)[C@@H]1O[C@@H](C)[C@H](O)[C@@H](O)[C@H]1O BNMGUJRJUUDLHW-HCZMHFOYSA-N 0.000 description 1
- BNMGUJRJUUDLHW-HLUHVYOBSA-N Madecassoside Natural products C[C@@H]1CC[C@@]2(CC[C@]3(C)C(=CC[C@@H]4[C@@]5(C)C[C@@H](O)[C@H](O)[C@@](C)(CO)[C@@H]5[C@H](O)C[C@@]34C)[C@@H]2[C@H]1C)C(=O)O[C@@H]6O[C@H](CO[C@@H]7O[C@H](CO)[C@@H](O[C@@H]8O[C@H](C)[C@H](O)[C@@H](O)[C@H]8O)[C@H](O)[C@H]7O)[C@@H](O)[C@H](O)[C@H]6O BNMGUJRJUUDLHW-HLUHVYOBSA-N 0.000 description 1
- 206010072170 Skin wound Diseases 0.000 description 1
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 1
- 206010053615 Thermal burn Diseases 0.000 description 1
- 206010048038 Wound infection Diseases 0.000 description 1
- 230000016571 aggressive behavior Effects 0.000 description 1
- 230000002009 allergenic effect Effects 0.000 description 1
- 230000004075 alteration Effects 0.000 description 1
- 230000003110 anti-inflammatory effect Effects 0.000 description 1
- 230000037444 atrophy Effects 0.000 description 1
- 230000001580 bacterial effect Effects 0.000 description 1
- 244000052616 bacterial pathogen Species 0.000 description 1
- 230000008901 benefit Effects 0.000 description 1
- 230000000740 bleeding effect Effects 0.000 description 1
- 229940082484 carbomer-934 Drugs 0.000 description 1
- 230000004640 cellular pathway Effects 0.000 description 1
- 229920001436 collagen Polymers 0.000 description 1
- 239000002131 composite material Substances 0.000 description 1
- 239000006071 cream Substances 0.000 description 1
- 230000008021 deposition Effects 0.000 description 1
- 238000010586 diagram Methods 0.000 description 1
- 230000008020 evaporation Effects 0.000 description 1
- 238000001704 evaporation Methods 0.000 description 1
- 210000002744 extracellular matrix Anatomy 0.000 description 1
- 230000004761 fibrosis Effects 0.000 description 1
- 230000009760 functional impairment Effects 0.000 description 1
- 230000003179 granulation Effects 0.000 description 1
- 238000005469 granulation Methods 0.000 description 1
- 239000000017 hydrogel Substances 0.000 description 1
- 230000001969 hypertrophic effect Effects 0.000 description 1
- 208000015181 infectious disease Diseases 0.000 description 1
- 238000002347 injection Methods 0.000 description 1
- 239000007924 injection Substances 0.000 description 1
- 208000014674 injury Diseases 0.000 description 1
- 230000003993 interaction Effects 0.000 description 1
- 210000001117 keloid Anatomy 0.000 description 1
- 230000002147 killing effect Effects 0.000 description 1
- 238000002430 laser surgery Methods 0.000 description 1
- 238000002647 laser therapy Methods 0.000 description 1
- 229940090813 madecassoside Drugs 0.000 description 1
- 230000007246 mechanism Effects 0.000 description 1
- 244000000010 microbial pathogen Species 0.000 description 1
- 239000002674 ointment Substances 0.000 description 1
- 230000037361 pathway Effects 0.000 description 1
- 239000008363 phosphate buffer Substances 0.000 description 1
- 230000035790 physiological processes and functions Effects 0.000 description 1
- -1 polysiloxane Polymers 0.000 description 1
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 description 1
- 238000001959 radiotherapy Methods 0.000 description 1
- 239000002994 raw material Substances 0.000 description 1
- 239000012488 sample solution Substances 0.000 description 1
- 210000004927 skin cell Anatomy 0.000 description 1
- 239000011780 sodium chloride Substances 0.000 description 1
- 230000001954 sterilising effect Effects 0.000 description 1
- 238000004659 sterilization and disinfection Methods 0.000 description 1
- 210000000434 stratum corneum Anatomy 0.000 description 1
- 239000000725 suspension Substances 0.000 description 1
- 238000001308 synthesis method Methods 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
- 238000002560 therapeutic procedure Methods 0.000 description 1
- 230000008719 thickening Effects 0.000 description 1
- 210000001519 tissue Anatomy 0.000 description 1
- 230000007838 tissue remodeling Effects 0.000 description 1
- 230000008733 trauma Effects 0.000 description 1
Images
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L26/00—Chemical aspects of, or use of materials for, wound dressings or bandages in liquid, gel or powder form
- A61L26/0057—Ingredients of undetermined constitution or reaction products thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L26/00—Chemical aspects of, or use of materials for, wound dressings or bandages in liquid, gel or powder form
- A61L26/0009—Chemical aspects of, or use of materials for, wound dressings or bandages in liquid, gel or powder form containing macromolecular materials
- A61L26/0014—Chemical aspects of, or use of materials for, wound dressings or bandages in liquid, gel or powder form containing macromolecular materials obtained by reactions only involving carbon-to-carbon unsaturated bonds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L26/00—Chemical aspects of, or use of materials for, wound dressings or bandages in liquid, gel or powder form
- A61L26/0009—Chemical aspects of, or use of materials for, wound dressings or bandages in liquid, gel or powder form containing macromolecular materials
- A61L26/0019—Chemical aspects of, or use of materials for, wound dressings or bandages in liquid, gel or powder form containing macromolecular materials obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L26/00—Chemical aspects of, or use of materials for, wound dressings or bandages in liquid, gel or powder form
- A61L26/0009—Chemical aspects of, or use of materials for, wound dressings or bandages in liquid, gel or powder form containing macromolecular materials
- A61L26/0023—Polysaccharides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L26/00—Chemical aspects of, or use of materials for, wound dressings or bandages in liquid, gel or powder form
- A61L26/0009—Chemical aspects of, or use of materials for, wound dressings or bandages in liquid, gel or powder form containing macromolecular materials
- A61L26/0028—Polypeptides; Proteins; Degradation products thereof
- A61L26/0047—Specific proteins or polypeptides not covered by groups A61L26/0033 - A61L26/0042
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L26/00—Chemical aspects of, or use of materials for, wound dressings or bandages in liquid, gel or powder form
- A61L26/0061—Use of materials characterised by their function or physical properties
- A61L26/0066—Medicaments; Biocides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L26/00—Chemical aspects of, or use of materials for, wound dressings or bandages in liquid, gel or powder form
- A61L26/0061—Use of materials characterised by their function or physical properties
- A61L26/008—Hydrogels or hydrocolloids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L2300/00—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices
- A61L2300/20—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices containing or releasing organic materials
- A61L2300/21—Acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L2300/00—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices
- A61L2300/20—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices containing or releasing organic materials
- A61L2300/216—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices containing or releasing organic materials with other specific functional groups, e.g. aldehydes, ketones, phenols, quaternary phosphonium groups
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L2300/00—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices
- A61L2300/20—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices containing or releasing organic materials
- A61L2300/252—Polypeptides, proteins, e.g. glycoproteins, lipoproteins, cytokines
- A61L2300/254—Enzymes, proenzymes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L2300/00—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices
- A61L2300/20—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices containing or releasing organic materials
- A61L2300/30—Compounds of undetermined constitution extracted from natural sources, e.g. Aloe Vera
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L2300/00—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices
- A61L2300/40—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices characterised by a specific therapeutic activity or mode of action
- A61L2300/404—Biocides, antimicrobial agents, antiseptic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L2300/00—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices
- A61L2300/40—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices characterised by a specific therapeutic activity or mode of action
- A61L2300/412—Tissue-regenerating or healing or proliferative agents
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Abstract
一种促进创面无瘢痕愈合的抗菌敷料及其制备方法。所述敷料按重量份计,由下述组分构成:超支化聚赖氨酸抗瘢痕复合物0.05‑0.1份,卡波姆0.1‑2.0份,增稠剂1‑10份,保湿剂2‑12份,水60‑90份,植物提取物1‑15份;并由碱调节pH至6.8~7.2。超支化聚赖氨酸与抗瘢痕药物通过化学方法接枝合成的一种新的复合物,既保留了超支化聚赖氨酸的抗菌活性,又保留了抗瘢痕药物抑制伤口形成瘢痕的能力,同时通过成膜剂可以在皮肤表面形成一层透气性和保湿性良好的膜,使创面保持湿润环境,有益于伤口愈合并且不产生瘢痕。
Description
本发明涉及一种促进创面无瘢痕愈合的抗菌敷料及其制备方法,属于生物医用技术领域。
皮肤是人体最大的器官,是连接内外环境的必要界面。因此,它持续保护身体免受外界的有害侵袭,从而也是人体极易受伤的器官。受伤后的皮肤仍然不可避免地会与环境中的各种病原微生物接触,如果在创面未闭合前发生感染,轻则延长愈合时间,重则导致病人的死亡。因此,抗菌性是敷料至关重要的性能之一。
瘢痕是皮肤创面愈合阶段在炎症、增殖及组织重塑等因素相互作用的结果。尽管瘢痕形成的机理仍不清楚,但通常认为创面愈合过程中的过度炎症会导致瘢痕。病理性瘢痕是在床上过程中由于各种内外因素导致的病理性结果,包括增生性瘢痕和瘢痕疙瘩,表现为胶原等大量细胞外基质过度沉积和成纤维细胞过度增殖。瘢痕生长超过一定的限度就会产生各种并发症,诸如外形的破坏及功能活动障碍等,给患者带来极大的肉体痛苦和精神痛苦,尤其是烧伤、烫伤、严重外伤后遗留的瘢痕,如若不做好措施很难消除。瘢痕增生期的几年时间让患者苦不堪言,而后的萎缩期又使患者面目全非,功能障碍,给患者造成极大的身心伤害。因此,有效抑制瘢痕的形成也是敷料至关重要的性能之一。
目前治疗瘢痕的方法主要有涂抹瘢痕膏、穿弹力衣、浅层放疗、注射治疗、激光治疗以及手术治疗等。这些方法各有优劣,但尚无哪种方法可以达到完美的效果。目前市场上的敷料大多是以单一的聚硅氧烷按不同比例制成的硅凝胶或者通过降低炎症水平来防治瘢痕,使水分蒸发减少,皮肤水分只留在角质层,使间质内水溶性蛋白及低分子水溶性物质向表面扩散,间质水溶性物质减少,瘢痕组织软化。然而硅凝胶功能单一,并且只能用于闭合创面,治疗效果欠佳;单独靠降低炎症水平预防瘢痕的效果也有限。CN 112704691A中公布了一种促进创面愈合及减少瘢痕形成的中药膏剂,可以降低创面愈合过程中的炎症水平,并具有一 定抗菌效果。但是却无法有效给创面提供一个湿润的环境,根据“湿性愈合理论”,创面护理时创造接近生理状态的湿性愈合环境,就有利于肉芽的生长,便于皮肤细胞的分裂,从而促使伤口的完整愈合创面。
发明内容
本发明的目的之一是提供一种可以在创面闭合前使用的凝胶敷料,该敷料可以为创面愈合提供一个良好的湿性环境;本发明的目的之二是提供一种在创面闭合前使用的抗菌凝胶敷料,该敷料在为创面愈合提供湿性环境的同时,还可以有广谱的抗菌效果,对常见致病菌有优异的杀灭作用,避免创面感染,促进创面愈合;本发明的目的之三是为提供一种可以在创面闭合前使用的有促进伤口无瘢痕愈合的抗菌凝胶敷料。此外,在该敷料中存在的药物有减轻炎症的效果和靶向作用于下游蛋白等与瘢痕形成相关的细胞通路的效果,可以有效促进创面无瘢痕愈合。
本发明的目的之一是通过以下技术方案实现的.
一种促进创面无瘢痕愈合的抗菌敷料,包括以下质量份的原料:
超支化聚赖氨酸抗瘢痕复合物0.05-0.1份,卡波姆0.1-2.0份,增稠剂1-10份,保湿剂2-12份,水60-90份,植物提取物1-10份。
优选地,所述植物提取物为芦荟提取液、仙人掌提取液中的至少一种。
优选地,所述保湿剂为甘油。
优选地,所述增稠剂为聚乙烯醇、羟丙甲基纤维素、羟乙基纤维素、聚乙烯吡咯烷酮中的一种或多种。
优选地,所述卡波姆为卡波姆系列产品,包括卡波姆910、卡波姆934、卡波姆934P、卡波密940、卡波姆941中的至少一种。
优选地,所述水为去离子水。
一种促进创面无瘢痕愈合的抗菌敷料的制备方法,包括如下步骤:
(1)将1-10份增稠剂与2-12份保湿剂加入到60-90份去离子水中磁搅拌溶解均匀,再加入1-10份植物提取物,真空下充分搅拌溶解待用。
(2)将0.1-2.0份卡波姆加入到90-100份水中真空磁搅拌溶解。
(3)将上述(1)和(2)中制备好的溶液混合均匀,加入碱溶液调节pH到6.8-7.2, 即可得到能使用到未闭合创面的凝胶敷料,以下称空白凝胶敷料。
本发明的目的之二是通过如下技术方案实现:
将超支化聚赖氨酸加入到空白凝胶敷料中,真空磁搅拌混合均匀,得到一种促进伤口的抗菌凝胶敷料。
本发明的目的之三是通过如下技术方案实现:
(1)取一定量超支化聚赖氨酸配制成10-30mg/mL的水溶液。新鲜的10-40mg/mL 2-亚氨基硫烷盐酸盐(2-IT)原液与超支化聚赖氨酸溶液按体积比3:1混合,室温下温和反应两小时,将反应液旋蒸并用异丙醇重复洗涤旋蒸,再在真空烘箱中干燥至质量恒定(25℃)。然后将得到的巯基改性的超支化聚赖氨酸与抗瘢痕药物(积雪草苷或丹酚酸B或木瓜蛋白酶)按质量比1:1溶于水,配制成10-20mg/mL的溶液,在50℃条件下反应5小时,将反应液旋蒸并用异丙醇重复洗涤旋蒸,再在真空烘箱中干燥至质量恒定(25℃),最后得到超支化聚赖氨酸抗瘢痕复合物。
(2)称取1-30份超支化聚赖氨酸与1-30份抗瘢痕药物,加入100份去离子水中,搅拌至完全溶解,得到混合溶液。称取0.6份1-乙基-(3-二甲基氨基丙基)碳酰二亚胺(EDC)和0.3份N-羟基琥珀酰亚胺(NHS)加入上述混合溶液中,再以2-(N-吗啡啉)乙撑磺酸(NHS)调节pH至5.5,常温下磁搅拌反应5-10小时。再将反应液旋蒸并用异丙醇重复洗涤旋蒸,最后得到的产物在真空烘箱中干燥至质量恒定(25℃),最后得到超支化聚赖氨酸抗瘢痕复合物。
然后将制备好的超支化聚赖氨酸抗瘢痕复合物配制成水溶液加入到空白凝胶敷料中,真空磁搅拌混合均匀,即可得到一种促进创面无瘢痕愈合的抗菌凝胶敷料。
本发明的有益效果是:
本发明通过将超支化聚赖氨酸与抗瘢痕药物通过化学方法接枝合成的一种全新的复合物,并通过组分的配合,得到具有优异促进创面无瘢痕愈合效果的抗菌凝胶敷料,该敷料可以在未愈合的创面表面形成一层透气性和保湿性良好的膜,使创面保持湿润环境,有益于伤口愈合并且不产生瘢痕。
图1本发明制备的水凝胶敷料的展示图
下面,结合具体实施方式,对本发明做进一步描述。需要说明的是,在不相冲突的前提下,以下描述的各实施例之间或各技术特征之间可以任意组合形成新的实施例。
实施例1:
取一定量超支化聚赖氨酸配制成30mg/mL的水溶液,新鲜的30mg/mL 2-亚氨基硫烷盐酸盐(2-IT)原液与超支化聚赖氨酸溶液按体积比3:1混合,室温下温和反应两小时,将反应液旋蒸并用异丙醇重复洗涤旋蒸,再在真空烘箱中干燥至质量恒定(25℃)。然后将得到的巯基改性的超支化聚赖氨酸与抗瘢痕药物积雪草苷按质量比1:1溶于水,配制成15mg/mL的溶液,在50℃条件下反应5小时,将反应液旋蒸并用异丙醇重复洗涤旋蒸,再在真空烘箱中干燥至质量恒定(25℃),最后得到超支化聚赖氨酸抗瘢痕复合物
按重量份数计,分别称取3份芦荟提取液、7份仙人掌提取液、15份增稠剂、上述制备的制备超支化聚赖氨酸抗瘢痕复合物0.1份,再称取10份甘油与80份去离子充分搅拌溶解均匀待用;将2.0份卡波姆940加入到80份水中,加热到60℃,使卡波姆940充分溶解在水中,待冷却到室温后倒入上述备好的增稠剂溶液中,充分搅拌溶解,最后加入适量pH调节剂,将pH调节至6.8-7.2,得到一种促进创面无瘢痕愈合的抗菌凝胶敷料,其外观展示图如图1所示,本发明制备的凝胶敷料是一种不易流动的凝胶。
实施例2
取一定量超支化聚赖氨酸配制成30mg/mL的水溶液,新鲜的30mg/mL 2-亚氨基硫烷盐酸盐(2-IT)原液与超支化聚赖氨酸溶液按体积比3:1混合,室温下温和反应两小时,将反应液旋蒸并用异丙醇重复洗涤旋蒸,再在真空烘箱中干燥至质量恒定(25℃)。然后将得到的巯基改性的超支化聚赖氨酸与抗瘢痕药物丹酚酸B按质量比1:1溶于水,配制成15mg/mL的溶液,在50℃条件下反应5小时,将反应液旋蒸并用异丙醇重复洗涤旋蒸,再在真空烘箱中干燥至质量恒定(25℃),最后得到超支化聚赖氨酸抗瘢痕复合物,
按重量份数计,分别称取3份芦荟提取液、7份仙人掌提取液、15份增稠剂、按上述制备的超支化聚赖氨酸抗瘢痕复合物0.1份,10份甘油与80份去离子充分搅拌溶解均匀待用;将2.0份卡波姆940加入到80份水中,加热到60℃,使卡波姆940充分溶解在水中,待冷却到室温后倒入上述备好的增稠剂溶液中,充分搅拌溶解,最后加入适量pH调节剂,将pH调节至6.8-7.2,得到一种促进创面无瘢痕愈合的抗菌凝胶敷料。
实施例3
取一定量超支化聚赖氨酸配制成30mg/mL的水溶液,新鲜的30mg/mL 2-亚氨基硫烷盐酸盐(2-IT)原液与超支化聚赖氨酸溶液按体积比3:1混合,室温下温和反应两小时,将反应液旋蒸并用异丙醇重复洗涤旋蒸,再在真空烘箱中干燥至质量恒定(25℃)。然后将得到的巯基改性的超支化聚赖氨酸与抗瘢痕药物木瓜蛋白酶按质量比1:1溶于水,配制成15mg/mL的溶液,在50℃条件下反应5小时,将反应液旋蒸并用异丙醇重复洗涤旋蒸,再在真空烘箱中干燥至质量恒定(25℃),最后得到超支化聚赖氨酸抗瘢痕复合物。
按重量份数计,分别称取3份芦荟提取液、7份仙人掌提取液、15份增稠剂,上述制备的超支化聚赖氨酸抗瘢痕复合物0.1份,再称取10份甘油与80份去离子充分搅拌溶解均匀待用;将2.0份卡波姆940加入到80份水中,加热到60℃,使卡波姆940充分溶解在水中,待冷却到室温后倒入上述备好的增稠剂溶液中,充分搅拌溶解,最后加入适量pH调节剂,将pH调节至6.8-7.2,得到一种促进创面无瘢痕愈合的抗菌凝胶敷料。
实施例4
称取30份超支化聚赖氨酸与30份积雪草苷,加入100份去离子水中,搅拌至完全溶解,得到混合溶液。称取0.6份1-乙基-(3-二甲基氨基丙基)碳酰二亚胺(EDC)和0.3份N-羟基琥珀酰亚胺(NHS)加入上述混合溶液中,再以2-(N-吗啡啉)乙撑磺酸(NHS)调节pH至5.5,常温下磁搅拌反应5-10小时。再将反应液旋蒸并用异丙醇重复洗涤旋蒸,最后得到的产物在真空烘箱中干燥至质量恒定(25℃),最后得到超支化聚赖氨酸抗瘢痕复合物。
按重量份数计,分别称取3份芦荟提取液、7份仙人掌提取液、15份增稠剂、上述制备的超支化聚赖氨酸抗瘢痕复合物0.1份、10份甘油与80份去离子充分 搅拌溶解均匀待用;将2.0份卡波姆940加入到80份水中,加热到60℃,使卡波姆940充分溶解在水中,待冷却到室温后倒入上述备好的增稠剂溶液中,充分搅拌溶解,最后加入适量pH调节剂,将pH调节至6.8-7.2,得到一种促进创面无瘢痕愈合的抗菌凝胶敷料。
实施例5
称取30份超支化聚赖氨酸与30份丹酚酸B,加入100份去离子水中,搅拌至完全溶解,得到混合溶液。称取0.6份1-乙基-(3-二甲基氨基丙基)碳酰二亚胺(EDC)和0.3份N-羟基琥珀酰亚胺(NHS)加入上述混合溶液中,再以2-(N-吗啡啉)乙撑磺酸(NHS)调节pH至5.5,常温下磁搅拌反应5-10小时。再将反应液旋蒸并用异丙醇重复洗涤旋蒸,最后得到的产物在真空烘箱中干燥至质量恒定(25℃),最后得到超支化聚赖氨酸抗瘢痕复合物。
按重量份数计,分别称取3份芦荟提取液、7份仙人掌提取液、15份增稠剂,上述制备的超支化聚赖氨酸抗瘢痕复合物0.1份、10份甘油与80份去离子充分搅拌溶解均匀待用;将2.0份卡波姆940加入到80份水中,加热到60℃,使卡波姆940充分溶解在水中,待冷却到室温后倒入上述备好的增稠剂溶液中,充分搅拌溶解,最后加入适量pH调节剂,将pH调节至6.8-7.2,得到一种促进创面无瘢痕愈合的抗菌凝胶敷料。
实施例6
称取30份超支化聚赖氨酸与30份木瓜蛋白酶,加入100份去离子水中,搅拌至完全溶解,得到混合溶液。称取0.6份1-乙基-(3-二甲基氨基丙基)碳酰二亚胺(EDC)和0.3份N-羟基琥珀酰亚胺(NHS)加入上述混合溶液中,再以2-(N-吗啡啉)乙撑磺酸(NHS)调节pH至5.5,常温下磁搅拌反应5-10小时。再将反应液旋蒸并用异丙醇重复洗涤旋蒸,最后得到的产物在真空烘箱中干燥至质量恒定(25℃),最后得到超支化聚赖氨酸抗瘢痕复合物。
按重量份数计,分别称取3份芦荟提取液、7份仙人掌提取液、15份增稠剂,上述制备的超支化聚赖氨酸抗瘢痕复合物0.1份、10份甘油与80份去离子充分搅拌溶解均匀待用;将2.0份卡波姆940加入到80份水中,加热到60℃,使卡波姆940充分溶解在水中,待冷却到室温后倒入上述备好的增稠剂溶液中,充分搅拌溶解,最后加入适量pH调节剂,将pH调节至6.8-7.2,得到一种促进创面 无瘢痕愈合的抗菌凝胶敷料。
本凝胶敷料透气、保湿性好,具有抗菌、无致敏、安全舒适、自然环保的特性。本敷料还具有抗菌消炎、促进伤口愈合、止血、吸湿保湿、抑制瘢痕增生、良好的生物相容性的作用。本敷料中使用的超支化聚赖氨酸抗瘢痕复合物含有大量末端基为氨基的结构,具有高效安全的杀菌效果和瘢痕抑制效果。
在实验室条件下,检测所有实施例制备得到的凝胶敷料对大肠杆菌、金黄色葡萄球菌、白色念珠菌以及绿脓杆菌的灭菌效果。具体检测方法参考15979-2002《一次性使用卫生用品卫生标准》附录C4进行试验,用每个实施例样品原液,与细菌共培养16小时,试验温度37℃。大肠杆菌、金黄色葡萄球菌、白色念珠菌、绿脓杆菌的菌种代数为4代,并用含0.03mol/L的磷酸盐缓冲液(PBS)配制菌悬液。同时通过靶向下游蛋白,下调成纤维细胞的通路,抑制伤口的纤维化,从而达到抑制瘢痕增生的效果。
抗菌实验数据如下表
从上表数据可见,抗瘢痕药物的选择以及复合物的合成方法不影响本发明制备的凝胶敷料的抗菌性能。
尽管已经示出和描述了本实用新型的实施例,对于本领域的普通技术人员而言,可以理解在不脱离本发明的原理和精神的情况下可以对这些实施例进行多种变化、修改、替换和变型,本发明的范围由所附权利要求及其等同物限定。
Claims (10)
- 一种促进创面无瘢痕愈合的抗菌敷料,其特征在于,所述敷料按重量份计,由下述组分构成:超支化聚赖氨酸抗瘢痕复合物0.05-0.1份,卡波姆0.1-2.0份,增稠剂1-10份,保湿剂2-12份,水150-200份,植物提取物1-15份;并由碱调节pH至6.8~7.2。
- 根据权利要求1所述的一种促进创面无瘢痕愈合的抗菌敷料,其特征在于,所述的增稠剂为聚乙烯醇、羟丙甲基纤维素、羟乙基纤维素、聚乙烯吡咯烷酮中的至少一种。
- 根据权利要求1所述的一种促进创面无瘢痕愈合的抗菌敷料,其特征在于,所述的保湿剂为甘油。
- 根据权利要求1所述的一种促进创面无瘢痕愈合的抗菌敷料,其特征在于,所述的植物提取物为芦荟提取液、仙人掌提取液中的至少一种。
- 根据权利要求1所述的一种促进创面无瘢痕愈合的抗菌敷料,其特征在于,所述的超支化聚赖氨酸抗瘢痕复合物的制备方法有以下两种:(1)巯基(-SH)化的超支化聚赖氨酸与抗瘢痕药物通过迈克尔加成合成复合物,(2)通过1-乙基-(3-二甲基氨基丙基)碳酰二亚胺催化超支化聚赖氨酸与抗瘢痕药物而合成的复合物。
- 根据权利要求5所述的一种促进创面无瘢痕愈合的抗菌敷料,其特征在于,所述的抗瘢痕药物为积雪草苷、丹酚酸B和木瓜蛋白酶中的至少一种。
- 根据权利要求5所述的一种促进创面无瘢痕愈合的抗菌敷料,其特征在于,所述超支化聚赖氨酸抗瘢痕复合物采用如下方法制得:取超支化聚赖氨酸配制成10-30mg/mL的水溶液,新鲜的10-40mg/mL 2-亚氨基硫烷盐酸盐(2-IT)原液与超支化聚赖氨酸溶液按体积比3:1混合,室温下反应,将反应液旋蒸并用异丙醇重复洗涤旋蒸,再在真空烘箱中干燥至质量恒定(25℃);将得到的巯基改性的超支化聚赖氨酸与抗瘢痕药物按质量比1:1溶于水,配制成总浓度10-20mg/mL的溶液,在50℃条件下反应5小时,将反应液旋蒸并用异丙醇重复洗涤旋蒸,再在真空烘箱中干燥至质量恒定(25℃),得到超支化聚赖 氨酸抗瘢痕复合物。
- 根据权利要求5所述的一种促进创面无瘢痕愈合的抗菌敷料,其特征在于,所述超支化聚赖氨酸抗瘢痕复合物采用如下方法制得:按质量计,称取1-30份超支化聚赖氨酸与1-30份抗瘢痕药物,加入100份去离子水中,搅拌至完全溶解,得到混合溶液;称取0.6份1-乙基-(3-二甲基氨基丙基)碳酰二亚胺和0.3份N-羟基琥珀酰亚胺加入上述混合溶液中,再以2-(N-吗啡啉)乙撑磺酸调节pH至5.5,常温下磁搅拌反应5-10小时;再将反应液旋蒸并用异丙醇重复洗涤旋蒸,最后得到的产物在真空烘箱中干燥至质量恒定(25℃),得到超支化聚赖氨酸抗瘢痕复合物。
- 根据权利要求1所述的一种促进创面无瘢痕愈合的抗菌敷料,其特征在于,采用如下方法制得:将1-10份增稠剂与2-12份保湿剂加入到60-90份去离子水中磁搅拌溶解均匀,再加入1-10份植物提取物,真空下充分搅拌溶解待用;将0.1-2.0份卡波姆加入到90-100份水中真空磁搅拌溶解;将制备好的两种溶液混合均匀,加入碱溶液调节pH到6.8-7.2;将超支化聚赖氨酸抗瘢痕复合物加入所得溶液中,磁搅拌混合均匀后离心脱泡,得到促进创面无瘢痕愈合的抗菌敷料。
- 根据权利要求9所述的一种促进创面无瘢痕愈合的抗菌敷料,其特征在于,所述的碱为三乙醇胺、氢氧化钠、磷酸盐缓冲液中的至少一种。
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN202210600635.X | 2022-05-30 | ||
CN202210600635.XA CN114984301B (zh) | 2022-05-30 | 2022-05-30 | 一种促进创面无瘢痕愈合的抗菌敷料及其制备方法 |
Publications (1)
Publication Number | Publication Date |
---|---|
WO2023231049A1 true WO2023231049A1 (zh) | 2023-12-07 |
Family
ID=83030853
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/CN2022/097163 WO2023231049A1 (zh) | 2022-05-30 | 2022-06-06 | 一种促进创面无瘢痕愈合的抗菌敷料及其制备方法 |
Country Status (2)
Country | Link |
---|---|
CN (1) | CN114984301B (zh) |
WO (1) | WO2023231049A1 (zh) |
Cited By (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN117731829A (zh) * | 2024-02-21 | 2024-03-22 | 浙江格物致知生物科技有限公司 | 一种医用凝胶敷料及其制备方法 |
CN117731829B (zh) * | 2024-02-21 | 2024-05-10 | 浙江格物致知生物科技有限公司 | 一种医用凝胶敷料及其制备方法 |
Citations (8)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN1806855A (zh) * | 2005-11-30 | 2006-07-26 | 合肥恒星医疗用品有限公司 | 一种含植物有效成分的湿性创口敷料 |
CN1833649A (zh) * | 2006-01-11 | 2006-09-20 | 北京因科瑞斯生物制品研究所 | 一种具有促进创伤愈合的积雪苷凝胶及其制备方法 |
WO2008015190A2 (en) * | 2006-07-31 | 2008-02-07 | Laboratoires Besins International | Treatment and prevention of excessive scarring |
CN106075556A (zh) * | 2016-06-02 | 2016-11-09 | 四川奎星医用高分子制品有限责任公司 | 含有促进伤口愈合药物的医用复合壳聚糖凝胶 |
CN106563156A (zh) * | 2016-10-18 | 2017-04-19 | 江南大学 | 一种具有成膜性的凝胶创面敷料 |
US20200368270A1 (en) * | 2018-01-31 | 2020-11-26 | Changchun Institute Of Applied Chemistry, Chinese Academy Of Sciences | Branched polyamino acid bacteriostatic agent and application thereof |
CN112316205A (zh) * | 2020-11-16 | 2021-02-05 | 中国药科大学 | 一种积雪草苷外用凝胶敷料及其制备方法 |
CN113577377A (zh) * | 2021-08-17 | 2021-11-02 | 浙江大学 | 一种活性氧消除抗菌消炎水凝胶皮肤敷料及其制备方法 |
Family Cites Families (11)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN101822827A (zh) * | 2010-05-13 | 2010-09-08 | 仵小南 | 皮肤美容和瘢痕修复的制剂 |
CN103083282B (zh) * | 2011-11-03 | 2015-11-18 | 杭州济迩斯生物科技有限公司 | 一种水凝胶疤痕贴及其制备工艺 |
EP2916876B1 (en) * | 2012-11-06 | 2021-10-20 | Imbed Biosciences, Inc. | Methods and compositions for wound healing |
CN103755965A (zh) * | 2013-12-25 | 2014-04-30 | 南京工业大学 | 一种ε-聚赖氨酸水凝胶及其制备方法和应用 |
CN106975075A (zh) * | 2016-01-18 | 2017-07-25 | 云南白药集团无锡药业有限公司 | 木瓜蛋白酶脂质体凝胶剂制备方法及用途 |
EP3716996A1 (en) * | 2017-11-30 | 2020-10-07 | Hollister Incorporated | Wound debridement composition and method for treating wounds |
EP3723819A4 (en) * | 2017-12-11 | 2021-09-29 | Animal Ethics Pty Ltd | WOUND DRESSING |
CN108853573A (zh) * | 2018-07-17 | 2018-11-23 | 山东景仲生物科技有限公司 | 一种促进早期创面愈合并减轻瘢痕形成的水凝胶 |
CN111035803B (zh) * | 2019-11-07 | 2021-07-06 | 浙江大学 | 一种兼具抗感染及促进骨结合功能的钛植入体材料及其制备方法 |
CN111195216A (zh) * | 2020-01-08 | 2020-05-26 | 李虹 | 一种皮肤护理膜及其制备方法 |
CN114099604A (zh) * | 2021-11-04 | 2022-03-01 | 振德医疗用品股份有限公司 | 一种具有预防疤痕功能的生物敷料及其制备方法 |
-
2022
- 2022-05-30 CN CN202210600635.XA patent/CN114984301B/zh active Active
- 2022-06-06 WO PCT/CN2022/097163 patent/WO2023231049A1/zh unknown
Patent Citations (8)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN1806855A (zh) * | 2005-11-30 | 2006-07-26 | 合肥恒星医疗用品有限公司 | 一种含植物有效成分的湿性创口敷料 |
CN1833649A (zh) * | 2006-01-11 | 2006-09-20 | 北京因科瑞斯生物制品研究所 | 一种具有促进创伤愈合的积雪苷凝胶及其制备方法 |
WO2008015190A2 (en) * | 2006-07-31 | 2008-02-07 | Laboratoires Besins International | Treatment and prevention of excessive scarring |
CN106075556A (zh) * | 2016-06-02 | 2016-11-09 | 四川奎星医用高分子制品有限责任公司 | 含有促进伤口愈合药物的医用复合壳聚糖凝胶 |
CN106563156A (zh) * | 2016-10-18 | 2017-04-19 | 江南大学 | 一种具有成膜性的凝胶创面敷料 |
US20200368270A1 (en) * | 2018-01-31 | 2020-11-26 | Changchun Institute Of Applied Chemistry, Chinese Academy Of Sciences | Branched polyamino acid bacteriostatic agent and application thereof |
CN112316205A (zh) * | 2020-11-16 | 2021-02-05 | 中国药科大学 | 一种积雪草苷外用凝胶敷料及其制备方法 |
CN113577377A (zh) * | 2021-08-17 | 2021-11-02 | 浙江大学 | 一种活性氧消除抗菌消炎水凝胶皮肤敷料及其制备方法 |
Cited By (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN117731829A (zh) * | 2024-02-21 | 2024-03-22 | 浙江格物致知生物科技有限公司 | 一种医用凝胶敷料及其制备方法 |
CN117731829B (zh) * | 2024-02-21 | 2024-05-10 | 浙江格物致知生物科技有限公司 | 一种医用凝胶敷料及其制备方法 |
Also Published As
Publication number | Publication date |
---|---|
CN114984301B (zh) | 2023-03-17 |
CN114984301A (zh) | 2022-09-02 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
KR102132543B1 (ko) | 양이온성 살생물제를 포함하는 페트롤라툼-계 조성물 | |
CN103083713B (zh) | 一种无菌聚合创面覆盖物敷料 | |
WO2017011982A1 (zh) | 贻贝粘蛋白产品及其抑制皮肤炎症的应用 | |
JP4496375B2 (ja) | 創傷の治療又は処置のための薬剤 | |
EP2059206B1 (en) | Dry wound dressing and drug delivery system | |
JPH04500798A (ja) | 硫酸化糖類の用途 | |
CN107185031B (zh) | 一种具有生物活性的医用敷料及其制备方法 | |
CN106344956A (zh) | 一种壳聚糖抑菌促愈合凝胶及其制备方法 | |
AU2001264011B2 (en) | Use of biguanide derivatives for making a medicine having a wound healing effect | |
CN108187132A (zh) | 一种聚维酮碘水凝胶抗菌敷料及其制备方法 | |
CN108158995A (zh) | 一种含有壳聚糖的妇科用抗菌泡沫剂及其制备方法 | |
CN103182070B (zh) | 一种外用组合物、制剂及其应用 | |
CN108452293A (zh) | 一种妇科用凝胶及其制备方法 | |
CN108420789B (zh) | 一种苯扎氯铵外用溶液及其制备方法 | |
CN104306324A (zh) | 一种医用胶原蛋白凝胶剂及其制备方法 | |
JPH05506861A (ja) | 損傷されたかまたは病気になった組織の局所的処置用の組成物および方法 | |
CN104740141B (zh) | 一种抗菌喷剂及其制备方法 | |
RU2699362C2 (ru) | Композиция на основе наночастиц диоксида церия и полисахаридов бурых водорослей для лечения ран | |
RU2636530C2 (ru) | Фармацевтическая композиция для лечения ран и ожогов | |
CN106794140A (zh) | 基于活性物质稳定溶液的药物组合物 | |
WO2023231049A1 (zh) | 一种促进创面无瘢痕愈合的抗菌敷料及其制备方法 | |
CN111991417A (zh) | 一种具有生理响应性的次氯酸凝胶及其在皮肤创面中的应用 | |
RU2146136C1 (ru) | Антисептическое средство "катацел" | |
CN113456735B (zh) | 一种灭活益生菌草本凝胶及其制备方法和应用 | |
CN115584034A (zh) | 一种用于伤口修复的可注射水凝胶材料及其制备方法 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
121 | Ep: the epo has been informed by wipo that ep was designated in this application |
Ref document number: 22944376 Country of ref document: EP Kind code of ref document: A1 |